Safety, Reactogenicity and Immunogenicity Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals' Investigational RSV Vaccine (GSK3003891A), in Healthy Women

NCT02360475 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

507

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Virus Infections

Interventions

BIOLOGICAL: RSV vaccine GSK3003895A (formulation 1)
BIOLOGICAL: RSV vaccine GSK3003898A (formulation 2)
BIOLOGICAL: RSV vaccine GSK3003899A (formulation 3)
BIOLOGICAL: Boostrix

Sponsor

GlaxoSmithKline